Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | RAF1 | P04049 | 16/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042972 | 0.92 | ADORA2A (0.73) | ADORA2AADORA1RAF1CASP3CDK9 | |
| SCHEMBL5036467 | 0.88 | ADORA2A (0.77) | ADORA2AADORA1RAF1CASP3CDK9 | |
| SCHEMBL5036192 | 0.87 | ADORA2A (0.76) | ADORA2AADORA1RAF1CASP3CDK9 | |
| SCHEMBL5033977 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1RAF1MAPT | |
| SCHEMBL5037662 | 0.83 | ADORA2A (0.61) | ADORA2AADORA1RAF1THRBMAPT | |
| SCHEMBL5043994 | 0.83 | ADORA2A (0.51) | ADORA2AADORA1LMNAMAPT | |
| SCHEMBL5037854 | 0.81 | ADORA2A (0.66) | ADORA2AADORA1LMNAMAPT | |
| SCHEMBL5036181 | 0.80 | ADORA2A (0.66) | ADORA2AADORA1LMNAMAPT | |
| SCHEMBL5036100 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1MAPT | |
| SCHEMBL5036593 | 0.78 | ADORA2A (0.45) | ADORA2AADORA1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587799-B1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-6992083-B2 | deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide | HOFFMAN-LA ROCHE INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1587799-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152702-A1 | Benzoxazol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-05 | — | — | US | disclosed |
| WO-2004063177-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152702-A1 | Benzoxazol derivatives | P2RX3, P2RX2, P2RX1 | ADORA2A 11/4885ADORA1 8/4885RAF1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.